In a press release reported today, design company SmartShape announced human trials for a device to detect COVID-19 by rapid breath testing in under 3 minutes will begin in India.

Canary Health Technology and SmartShape Design, companies based in Cleveland, have cooperated to build ASU Detect CV19, a high-speed, highly accurate COVID-19 breath-testing instrument. The automated hand-held test needs limited preparation and can be carried out at the center without laboratory specifications.

Sinovac Confirms $500 Million Towards COVID-19 Vaccine Research
Sinovac Life Sciences has secured around US$500 million in funding to grow, expand capability and produce its COVID-19 vaccine candidate, CoronaVac...

ASU Detect CV19 is the first and largest clinical test in Delhi, India to use a real-time breath testing with cloud-based AI in order to detect an infectious disease as a method for evaluating the model. Tests are planned and are expected to start in the United States by the end of 2020. If the test works, Canary will easily apply for regulatory approval in a fast-track manner while continued testing in real life conditions such as airports, resorts, and other high-frequency locations.

The device is intended to detect the virus in people with symptoms or those asymptomatic with exhaled, organic compounds present in human breath as biomarkers of the virus. Although the viral load in a human is assessed by current accessible testing to assess if it is contaminated, the Canary Breath test nearly instantly after exposure identifies the metabolic reaction, culminating in test results in less than three minutes.

The CEO and inventor of breath sensing technology in Canary Health Technologies, Raj Reddy, believes the future of COVID-19 detection as well numerous other diseases will form part of the Canary Breath diagnostic network. "Our cutting-edge technology enables easy, rapid testing every few days in order to optimize safety in workplaces and other settings. Our unique strength will be our ability to detect COVID-19 in under three minutes before the onset of symptoms which will be critical in reducing transmission and ultimately putting an end to this pandemic," says Reddy.

This latest COVID-19 test can be established at high speed by Canaria, since the platform for detection of early stage lung cancer is already in progress. In February 2020, as the pandemic became apparent, the corporation rapidly conceived an ultra-fast test to open up the economy and relieve transmission, which was to lead to massive global disruption. Scientists and engineers from Canary focused on creating a mobile, cloud-based artificial intelligence test that is all available in real time for mass screening and monitoring.

For SmartShape CEO and creator Mike Maczuzak, Canary has been individually and professionally compensated by the sponsorship of industrial design and manufacturing. "As a consultancy, SmartShape helps invent, design and develop innovative new products across a broad spectrum of verticals, from medical devices to industrial and consumer products. We're involved with many exciting and emerging technologies, but when we can help develop a product that will impact and even save lives, that is incredibly satisfying. Everyone has been affected by this global pandemic and to know our team will have contributed to solving it – that really fuels my passion for healthcare innovation," Everybody is affected in this global sphere, and SMARTSHAPE also helps to create and develop new products that are innovative in a broad array of fields, from medical devices to industrial and consumer products.

COVID-19 Vaccine “High Priority” for Meat Industry
“The meat and poultry industry was among the first sectors to be challenged with the pandemic, and since March the industry has implemented effective programs and controls to stop the spread of COVID...

Canary is also creating a strong breath analysis platform for the diagnosis of cancer, respiratory diseases and inflammatory illness. In 2019, the platform was shown to detect lung cancer with high sensitivity and specificity in a clinical trial in Canada. In the U.S. and Asia in 2021 there are proposals to demonstrate definition and pivotal studies of many high-burden diseases.